Oral Antidiabetics Morocco 2026: Glucophage, Diamicron, Janumet

01Type 2 diabetes in Morocco 2026#

Type 2 diabetes affects about 10.6 % of Moroccan adults according to the national STEPS survey conducted by WHO and the Moroccan Ministry of Health (2017-2018), some 2.7 million adults of whom roughly half are unaware of their status. It is the leading cause of end-stage renal failure in the country, the second cause of acquired blindness, and triples the risk of cardiovascular events and stroke.

This article concerns adults only; in adolescents over 10, type 2 diabetes does occur (juvenile obesity is rising in Morocco) and metformin holds a marketing authorisation in this age group, but management mandatorily requires a paediatrician or paediatric endocrinologist.

Therapeutic target: maintain HbA1c between 6.5 and 7.5 % in most patients, with the target relaxed in frail elderly (8 % acceptable) or tightened during pregnancy (< 6 %).

02Metformin: the cornerstone for 70 years#

Metformin, marketed as Glucophage (Merck Serono) and as several generics (Metfor, Metformine Cooper, Metformine Sanofi), remains in 2026 the first-line drug recommended by SMEDIAN, ADA and EASD. Alogliptin, the most recently introduced gliptin in Morocco, available as Apxia 2.5 mg and Apxia 5 mg, broadens the DPP-4 inhibitor arsenal, particularly useful at reduced doses in moderate-to-severe renal impairment.

Mechanism: metformin reduces hepatic glucose production and improves muscle insulin sensitivity. It does not stimulate insulin secretion, which explains the absence of hypoglycaemia in monotherapy. Available strengths: 500, 850 and 1000 mg, two to three times daily during or after meals.

Digestive side effects (nausea, diarrhoea, bloating) affect 20-30 % of patients at the outset. The practical rule: start with 500 mg in the evening, mid-meal, for one week, then gradually escalate. Vitamin B12: deficiency occurs in 10-30 % after several years of treatment — annual measurement is recommended in at-risk patients.

Renal failure (2023 graded recommendations): eGFR 45-60 mL/min continue with monitoring; eGFR 30-45 reduce dose by 50 % (maximum 1000-1500 mg/day); eGFR < 30 contraindication. Other contraindications: severe hepatic impairment, decompensated heart failure, iodinated contrast CT scan (stop 48 h before and after).

During pregnancy, metformin remains contraindicated first-line per the SmPC; insulin is the reference treatment. Specialist use is possible only under joint endocrinologist + obstetrician supervision.

Glucophage 1000 mg box of 30: 35-45 MAD, generics 20-30 MAD. Diabetes = ALD (long-term condition) → AMO 100 % of TNR reimbursement.

03Sulfonylureas: Diamicron and pancreatic stimulation#

In Morocco, gliclazide (Diamicron 30 or 60 mg MR Servier, generics Diaglyc, Gliclazide Cooper) dominates, followed by glimepiride (Amarel) and more rarely glibenclamide (Daonil). These molecules bind SUR1 receptors on beta cells and trigger insulin release. Efficacy is 1 to 1.5 HbA1c points, but with significant hypoglycaemia risk.

Glibenclamide (Daonil) is strongly discouraged in patients over 65 and in any patient with even moderate renal impairment (eGFR < 60). It causes severe and prolonged hypoglycaemic episodes lasting 24-48 hours.

In overdose, treatment combines oral resugaring if consciousness is preserved, then glucagon 1 mg IM/SC injection (kits available in pharmacies), followed by systematic hospitalisation for hypertonic 10-30 % glucose infusion over 24-72 hours.

Critical interaction: combination with miconazole (Daktarin oral gel available over the counter, vaginal ovules) = absolute contraindication (severe, sometimes fatal hypoglycaemia). Also: NSAIDs, ACE inhibitors/ARBs, non-selective beta-blockers (which mask warning signs), fluoroquinolones.

Ramadan: per IDF-DAR and SMEDIAN guidance — prefer gliclazide MR, main dose at iftar, skip the suhoor dose if once-daily, halve the suhoor dose if twice-daily.

Diamicron 30 MR box of 30: 40-50 MAD, generics 25-35 MAD.

04Glitazones: pioglitazone#

The only molecule still marketed globally is pioglitazone. In Morocco in 2026: limited availability, marketing authorisation for the originator (Actos, imported) and a few generics in 15 mg, 30 mg and 45 mg. No pioglitazone presentation is marketed in 2.5 mg or 5 mg in Morocco.

Mechanism: activates PPAR-gamma receptors in adipose and muscle tissue and improves insulin resistance. Efficacy 1-1.5 HbA1c points. The IRIS trial (Kernan, NEJM 2016) showed a reduction in recurrent strokes, but in patients with prior stroke/TIA and insulin resistance, without overt diabetes — generalisation is therefore restricted.

Slow effect: 8-12 weeks to observe full benefit. Efficacy is not judged before 3 to 6 months.

Dosing: 15 mg/day at initiation, increased to 30 mg, ceiling 45 mg/day. During Ramadan, pioglitazone can be continued without dose modification.

Adverse effects: fluid retention (oedema 5-10 %), heart failure NYHA III/IV = formal contraindication. Weight gain 2-4 kg. Risk of atypical bone fractures in postmenopausal women. Confirmed bladder cancer risk per meta-analyses since the 2011 ANSM alert: absolute CI in case of history or unexplained gross haematuria. Urinary cytology + bladder ultrasound are recommended before initiation and annually.

05DPP-4 inhibitors: Januvia, Janumet, Apxia#

Sitagliptin (Januvia 100 mg MSD) and its fixed combination with metformin, Janumet (50 mg sitagliptin + 850 or 1000 mg metformin), dominate. Vildagliptin (Galvus, Galvus Met Novartis) complements the offer. Saxagliptin (Onglyza, Komboglyze) has seen its availability reduced — check BNDM. Alogliptin, available in Morocco in two strengths Apxia 2.5 mg and Apxia 5 mg, is prescribed in particular for patients with moderate-to-severe renal impairment where it is used at reduced doses.

Sitagliptin blocks GLP-1 and GIP degradation. Glucose-dependent effect → hypoglycaemia risk is dramatically reduced. Efficacy 0.6-0.8 HbA1c points.

Excellent tolerance profile: no hypoglycaemia, weight neutrality. Option of choice in frail elderly, patients fearing hypoglycaemia, and patients with renal failure with dose adjustment: 100 mg/d if eGFR ≥ 45, 50 mg if eGFR 30-45, 25 mg if eGFR < 30 including dialysis.

Rare but important adverse effects: nasopharyngitis, exceptional cases of acute pancreatitis (immediate discontinuation), cutaneous reactions, arthralgia. Important interaction: sitagliptin + ACE inhibitor = increased risk of angio-oedema.

Januvia 100 mg box of 28: 300-400 MAD, Janumet 50/1000 box of 56: 450-550 MAD. First sitagliptin generics expected 2026-2027.

06Overdose: emergency management#

For sulfonylureas, prolonged severe hypoglycaemia for 24-72 hours; oral resugaring if consciousness is preserved, glucagon 1 mg IM/SC otherwise, systematic hospitalisation for 10-30 % glucose infusion over 24-48 h.

For metformin, massive overdose (>5-10 g) or acute renal failure can trigger lactic acidosis (mortality 30-50 % in severe forms); correction of acidosis, haemodynamic support, early haemodialysis.

Immediate call to CAPM Rabat: +212 5 37 77 71 69.

07Choosing the right molecule#

ADA/EASD/SMEDIAN favour a personalised approach. New diabetic patient, HbA1c < 8.5 %: metformin + lifestyle measures. At 3 months if HbA1c > 7 %, add a second molecule according to profile. Major overweight + metabolic syndrome + no heart failure or bladder cancer: pioglitazone. Frail elderly: metformin + gliptin (Janumet). Young lean patient on limited budget: metformin + gliclazide.

SGLT2 inhibitors (Jardiance, Forxiga) and injectable GLP-1 analogues (Ozempic, Trulicity) have reshaped the algorithm since 2020 in patients at very high cardiovascular risk or with nephropathy. High cost (300-1200 MAD/month).

08Prices and AMO reimbursement#

Diabetes = ALD → AMO 100 % of TNR (not 70 %). Monthly cost: metformin alone 50-60 MAD. Metformin + gliclazide MR 90-110 MAD. Metformin + pioglitazone 100-150 MAD. Janumet 50/1000 × 2/day 450-600 MAD.

Self-monitoring glucose meters 200-600 MAD, test strips 250-450 MAD/box of 50. HbA1c in private 200-400 MAD, free in public. Private endocrinologist consultation 400-800 MAD.

09When to switch to insulin#

Beta-cell function declines by 3-5 % per year. Indications: HbA1c > 9 % despite maximal combination therapy, decompensation symptoms, ketoacidosis, pregnancy.

The most common scheme: single basal insulin at bedtime (Lantus, Toujeo, Abasaglar, Levemir, Tresiba), 10 units or 0.1-0.2 U/kg, titrated to fasting glucose. Metformin, pioglitazone and gliptins are generally kept; sulfonylureas are stopped.

10When to consult an endocrinologist-diabetologist#

Indications: initial diagnosis in a young patient, HbA1c > 8.5 % despite well-conducted dual therapy for 3-6 months, repeated hypoglycaemia, microvascular complications, pregnancy, major intercurrent events (corticosteroid therapy, surgery). Sahha directory to identify a specialist.

Annual workup: fundoscopy, microalbuminuria + creatinine, ECG, foot examination with monofilament, lipid panel, TSH every 2 years, annual B12 measurement in at-risk patients. Under pioglitazone: urinary cytology + bladder ultrasound annually.

11HbA1c targets 2026 and glycaemic monitoring#

The HbA1c < 7 % threshold remains the cornerstone target in adults with type 2 diabetes free of complications, aligned with the joint 2024-2026 recommendations of ADA, EASD and SMEDIAN. The target is relaxed to < 8 % in frail elderly or patients with limited life expectancy, in order to prevent severe hypoglycaemic episodes which trigger hip fractures and falls. In young recently diagnosed patients without comorbidities, some experts aim for < 6.5 % to slow progression toward microvascular complications such as retinopathy and nephropathy. Recommended capillary thresholds are fasting glucose < 130 mg/dL and post-prandial glucose < 180 mg/dL measured two hours after the start of the meal.

Time in range (TIR 70-180 mg/dL) derived from continuous glucose monitors has become a complementary marker validated by the international ATTD consensus, with the goal of more than 70 % of the day spent in range. In Morocco, FreeStyle Libre 2 and Dexcom G7 sensors are now available at a monthly cost of 800 to 1500 MAD, currently not reimbursed by AMO, which limits their uptake despite robust scientific evidence of benefit, especially in patients on multiple daily insulin injections or with recurrent hypoglycaemia.

12Cardiovascular outcomes evidence and SGLT2/GLP-1 positioning#

Joint 2024 ADA/EASD recommendations now place SGLT2 inhibitors (empagliflozin Jardiance, dapagliflozin Forxiga, canagliflozin Invokana) and GLP-1 receptor agonists (semaglutide Ozempic, dulaglutide Trulicity, liraglutide Victoza) as preferred second-line options — and even first-line in combination with metformin — in any patient at very high cardiovascular risk (prior myocardial infarction, stroke, symptomatic coronary disease), with heart failure (preserved or reduced ejection fraction), or with chronic kidney disease (eGFR 20-60 mL/min or microalbuminuria). The EMPA-REG OUTCOME trial (empagliflozin), DAPA-HF and DAPA-CKD (dapagliflozin), LEADER (liraglutide) and SUSTAIN-6 (semaglutide) demonstrated a 14 to 25 % reduction in major adverse cardiovascular events and slowed progression of diabetic nephropathy independently of glycaemic control.

GLP-1 analogues additionally trigger 4 to 15 kg of weight loss depending on molecule and dose, making them privileged options in obese patients. In Morocco, monthly cost remains a major barrier: 300 to 600 MAD/month for Jardiance or Forxiga, 700 to 1200 MAD/month for Ozempic (frequently out of stock nationally due to global demand fuelled by off-label obesity use), with AMO coverage still uneven. SMEDIAN advocates accelerated inclusion of these agents in the ALD reimbursement list, especially in patients with proven diabetic nephropathy where the benefit-to-cost ratio is most favourable.

13Medical disclaimer#

This article is strictly informational and in no way replaces the opinion of your treating physician or endocrinologist-diabetologist. Any treatment modification must be medically validated. In case of adverse effect, contact your doctor or the CAPM Rabat: +212 5 37 77 71 69. Management in children, adolescents, pregnant or breastfeeding women requires specialist consultation.